1stOncology™: Cancer Intelligence Service – Page 15704 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Oncopeptides to present at the Jefferies Healthcare Conference in New York on June 7th

On May 29, 2018 Oncopeptides AB (Nasdaq Stockholm: ONCO) reported that they will present at Jefferies annual Healthcare Conference in New York on June 7th at 1.30PM EST, the presentation will be webcasted (Press release, Oncopeptides, MAY 29, 2018, View Source [SID1234527103]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Oncopeptides is a research and development stage pharmaceutical company developing drugs for the treatment of cancer. Since the founding of the company, the focus has primarily been on the development of the lead product candidate Ygalo, an innovative, peptidase-potentiated alkylator intended for effective and focused treatment of hematological cancers, and in particular multiple myeloma.

Ygalo has been used to treat late-stage RRMM patients in both phase I and phase II clinical studies (O-12-M1) with favorable results. Currently, Ygalo is being studied in three clinical trials for the treatment of multiple myeloma. The current studies are HORIZON, OCEAN and ANCHOR. A fourth study, BRIDGE in RRMM patients with impaired renal function will be initiated during Q3 this year to further investigate Ygalo in multiple myeloma.

The current clinical study program is intended to demonstrate better results from treatment with Ygalo compared to established alternative drugs for patients with late-stage multiple myeloma. Ygalo could potentially provide physicians with a new treatment option for patients suffering from this serious disease.

Onconova Therapeutics, Inc. to Present at the 8th Annual LD Micro Invitational

On May 29, 2018 Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS), reported that it will be presenting at the 8th Annual LD Micro Invitational on Monday, June 4th at 9:00a PDT / 12:00p EDT at the Luxe Sunset Bel Air Hotel in Los Angeles (Press release, Onconova, MAY 29, 2018, View Source [SID1234527102]). Mr. Mark Guerin, Chief Financial Officer of Onconova, will be giving the presentation and meeting with investors.

"The event is slated to be our largest Invitational to date," stated Chris Lahiji, President of LD Micro. "When the fires caused the cancellation of our Main Event back in December, we vowed to come back even stronger. This event showcases our firm’s ability to attract the most unique and exciting names in micro-cap."

The conference will feature 230 companies in the small-cap / micro-cap space, and will be attended by over 1,000 individuals.

Medtronic to Participate In Goldman Sachs Global Healthcare Conference

On May 29, 2018 Medtronic plc (NYSE:MDT), the global leader in medical technology, reported that it will participate in the Goldman Sachs 39th Annual Global Healthcare Conference on Tuesday, June 12, 2018, in Rancho Palos Verdes, Calif (Press release, Medtronic, MAY 29, 2018, View Source;p=RssLanding&cat=news&id=2351076 [SID1234527091]).

Omar Ishrak, Medtronic chairman and chief executive officer, and Karen Parkhill, Medtronic executive vice president and chief financial officer, will answer questions about the company beginning at 8:00 a.m. PDT (10:00 a.m. CDT).

A live audio webcast of the session will be available on June 12, 2018, by clicking on the Investor Events link at View Source, and an archive of the session will be available on the same webpage later in the day.

Johnson & Johnson to Participate in the Goldman Sachs 39th Annual Global Healthcare Conference

On May 29, 2018 Johnson & Johnson (NYSE: JNJ) reported that it will participate in the Goldman Sachs 39th Annual Global Healthcare Conference on Tuesday, June 12, at the Terranea Resort in Rancho Palos Verdes, California (Press release, Johnson & Johnson, MAY 29, 2018, View Source [SID1234527088]). Tom Cavanaugh, President, Oncology, Janssen Pharmaceuticals and Scott White, President, Immunology will represent the Company in a session scheduled at 9:20 a.m. (Pacific Time).

This webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com.

A webcast and podcast replay will be available approximately two hours after the live webcast.

Ipsen and MD Anderson Announce Bench-to-Bedside Cancer Drug Development Partnership

On May 29, 2018 Ipsen (Euronext: IPN; ADR: IPSEY), a global biopharmaceutical group, and The University of Texas MD Anderson Cancer Center reported a global licensing and joint development agreement for a pre-clinical oncology drug candidate discovered by researchers in MD Anderson’s Institute for Applied Cancer Science (IACS) (Press release, Ipsen, MAY 29, 2018, View Source [SID1234527087]).

MD Anderson will progress the drug candidate through Phase I clinical development with Ipsen being responsible for further global development and commercialization.

Alexandre Lebeaut, M.D., Executive Vice President, Research & Development and Chief Scientific Officer, Ipsen, commented, "We are very pleased to partner with the IACS at the MD Anderson Cancer Center whose reputation in scientific excellence and clinical care in Oncology is outstanding. Through this collaboration, we aim to synergize IACS’ scientific expertise with Ipsen’s drug development capabilities to deliver innovative therapies more rapidly to patients in need, and advance patient care in Oncology"

MD Anderson and Ipsen also will collaborate to conduct additional pre-clinical studies to further explore the potential of the drug candidate’s mode-of-action and expanded indications. The detailed financial terms of the agreement, including development and commercial milestones and royalties, have not been disclosed.

"We believe this partnership has the potential to deliver a new therapeutic option to our patients," said Stephen Hahn, M.D., chief medical executive at MD Anderson. "This focus on accelerating the development of efficient treatments is vital to our mission of ending cancer and to providing the very best care we can to those who need it most."